Neurocrine Biosciences (NBIX) Property, Plant & Equipment (Net) (2010 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Property, Plant & Equipment (Net) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Property, Plant & Equipment (Net) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 23.58 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 5.80 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 25.74 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 10.69 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 19.03 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 113.37 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 34.61 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 709.47 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 1.93 Bn |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 90.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 90.50 Mn |
| Mar 31, 2026 | 90.90 Mn |
| Dec 31, 2025 | 89.80 Mn |
| Sep 30, 2025 | 97.30 Mn |
| Jun 30, 2025 | 91.70 Mn |
| Mar 31, 2025 | 87.00 Mn |
| Dec 31, 2024 | 82.60 Mn |
| Sep 30, 2024 | 80.00 Mn |
| Jun 30, 2024 | 80.10 Mn |
| Mar 31, 2024 | 75.30 Mn |
| Dec 31, 2023 | 70.80 Mn |
| Sep 30, 2023 | 68.80 Mn |
| Jun 30, 2023 | 65.60 Mn |
| Mar 31, 2023 | 62.80 Mn |
| Dec 31, 2022 | 58.60 Mn |
| Sep 30, 2022 | 60.90 Mn |
| Jun 30, 2022 | 66.80 Mn |
| Mar 31, 2022 | 63.90 Mn |
| Dec 31, 2021 | 58.60 Mn |
| Sep 30, 2021 | 51.10 Mn |